Irina V. Stanoevich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irina V. Stanoevich has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Uglesha Stanoyevich
Kursk State Medical University, Ministry of Health of Russia; G.E. Ostroverkhov Kursk Cancer Research and Clinical Center
6 shared publications - Дмитрий Владимирович Петроченко
Kursk State Medical University of the Ministry of Health of Russia; G.E. Ostroverkhov Kursk Cancer Research and Clinical Center
6 shared publications - Ekaterina V. Pis'MEnnaia
Ministry of Health of the Kursk Region
4 shared publications - Ilya E. Alekseev
Kursk Oncological Scientific and Clinical Center named after G.E. Ostroverkhov
4 shared publications - Natalya L. Lysovolenko
G.E. Ostroverkhov Kursk Cancer Research and Clinical Center
4 shared publications - Svetlana Yu. Vorotnikova
Federal State Budgetary Institution «National Medical Research Center for Endocrinology named after academician I.I. Dedova» of the Ministry of Health Russian Federation
4 shared publications
Latest Publications
- Open Access
- 8 May 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (2)
Clinical significance of assessing systemic trace element concentrations in gastric cancer patients during anticancer drug therapy
Введение. Нежелательные явления противоопухолевой терапии при раке желудка остаются серьезной клинической проблемой, ограничивающей проведение полного курса лечения. Нарушение микроэлементного баланса может способствовать развитию токсических осложнений и рассматриваться как возможная основа для персонализации терапии. Цель. Оценить связь между концентрацией меди, цинка, селена и марганца в плазме крови и частотой развития, характером и степенью тяжести токсических осложнений противоопухолевой лекарственной терапии у больных местнораспространенным и метастатическим раком желудка. Материалы и методы. В исследование включено 100 пациентов с впервые установленным диагнозом «рак желудка», прошедших четыре курса химиотерапии. Концентрации микроэлементов измерялись методом масс-спектрометрии с индуктивно-связанной плазмой (Varian 810-MS) непосредственно до проведения первого и пятого курса противоопухолевой лекарственной терапии. Тяжесть нежелательных явлений оценивалась по шкале CTCAE v5.0. Статистический анализ включал корреляцию Спирмена. Результаты. Абсолютные концентрации микроэлементов (меди, цинка, селена, марганца) в плазме крови больных раком желудка до первого и пятого курса химиотерапии не выходили за пределы референсных значений и слабо коррелировали с частотой, характером и степенью тяжести нежелательных явлений противоопухолевого лекарственного лечения (p > 0,05). Однако соотношения плазменных концентраций микроэлементов продемонстрировали значимые корреляции: соотношение медь/цинк до лечения коррелировало со снижением тяжести лейкопении (r = –0,331; p = 0,046) и диареи (r = –0,331; p = 0,001); соотношение селен/марганец до лечения ассоциировалось с уменьшением выраженности анемии (r = –0,211; p = 0,036); соотношения медь/марганец до лечения, цинк/селен до лечения и медь/цинк после четырех курсов химиотерапии показали обратные связи с диареей (r = –0,206, r = –0,199, r = –0,241 соответственно; p < 0,05). Заключение. Полученные результаты свидетельствуют о том, что предиктивной значимостью обладают не абсолютные концентрации исследованных микроэлементов в плазме крови больных до и в процессе лечения, а их соотношения. Полученные данные указывают на перспективность использования микроэлементных соотношений в многофакторных предиктивных моделях токсичности, где они могут выступать в качестве дополнительных и значимых маркеров наравне с генетическими, клинико–лабораторными и инструментальными предикторами.
- 8 May 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (2)
Open AccessClinical significance of assessing systemic trace element concentrations in gastric cancer patients during anticancer drug therapy
Введение. Нежелательные явления противоопухолевой терапии при раке желудка остаются серьезной клинической проблемой, ограничивающей проведение полного курса лечения. Нарушение микроэлементного баланса может способствовать развитию токсических осложнений и рассматриваться как возможная основа для персонализации терапии. Цель. Оценить связь между концентрацией меди, цинка, селена и марганца в плазме крови и частотой развития, характером и степенью тяжести токсических осложнений противоопухолевой лекарственной терапии у больных местнораспространенным и метастатическим раком желудка. Материалы и методы. В исследование включено 100 пациентов с впервые установленным диагнозом «рак желудка», прошедших четыре курса химиотерапии. Концентрации микроэлементов измерялись методом масс-спектрометрии с индуктивно-связанной плазмой (Varian 810-MS) непосредственно до проведения первого и пятого курса противоопухолевой лекарственной терапии. Тяжесть нежелательных явлений оценивалась по шкале CTCAE v5.0. Статистический анализ включал корреляцию Спирмена. Результаты. Абсолютные концентрации микроэлементов (меди, цинка, селена, марганца) в плазме крови больных раком желудка до первого и пятого курса химиотерапии не выходили за пределы референсных значений и слабо коррелировали с частотой, характером и степенью тяжести нежелательных явлений противоопухолевого лекарственного лечения (p > 0,05). Однако соотношения плазменных концентраций микроэлементов продемонстрировали значимые корреляции: соотношение медь/цинк до лечения коррелировало со снижением тяжести лейкопении (r = –0,331; p = 0,046) и диареи (r = –0,331; p = 0,001); соотношение селен/марганец до лечения ассоциировалось с уменьшением выраженности анемии (r = –0,211; p = 0,036); соотношения медь/марганец до лечения, цинк/селен до лечения и медь/цинк после четырех курсов химиотерапии показали обратные связи с диареей (r = –0,206, r = –0,199, r = –0,241 соответственно; p < 0,05). Заключение. Полученные результаты свидетельствуют о том, что предиктивной значимостью обладают не абсолютные концентрации исследованных микроэлементов в плазме крови больных до и в процессе лечения, а их соотношения. Полученные данные указывают на перспективность использования микроэлементных соотношений в многофакторных предиктивных моделях токсичности, где они могут выступать в качестве дополнительных и значимых маркеров наравне с генетическими, клинико–лабораторными и инструментальными предикторами.
- Open Access
- 23 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (6) , 956
Acromegalic Uteropathy: Specific Uterine Ultrasound Findings in Female Patients
Background/Objectives: Acromegaly is a systemic connective tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess; yet, the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n = 33), healthy controls (n = 45), and adenomyosis without acromegaly (n = 44). Uterine body measurements were obtained by TAUS/TVUS; cervical biometry was performed transvaginally in all cases. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p-values non-significant). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical width, AP thickness, and volume, together with altered U:C indices, whereas cervical length did not differ, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This noninvasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.
- 23 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (6) , 956
Open AccessAcromegalic Uteropathy: Specific Uterine Ultrasound Findings in Female Patients
Background/Objectives: Acromegaly is a systemic connective tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess; yet, the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n = 33), healthy controls (n = 45), and adenomyosis without acromegaly (n = 44). Uterine body measurements were obtained by TAUS/TVUS; cervical biometry was performed transvaginally in all cases. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p-values non-significant). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical width, AP thickness, and volume, together with altered U:C indices, whereas cervical length did not differ, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This noninvasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.
- Open Access
- 30 January 2026
- Published by MDPI AG in Preprints.org
Acromegalic Uteropathy: Specific Uterine Ultrasound Findings in Female Patients
Background/Objectives: Acromegaly is a systemic connective-tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess, yet the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n=33), healthy controls (n=45), and adenomyosis without acromegaly (n=44). Uterine body and cervical length, width, and anteroposterior (AP) dimensions were measured transvaginally/transabdominally. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p>0.1). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical dimensions and altered U:C indices, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This non-invasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.
- 30 January 2026
- Published by MDPI AG in Preprints.org
Open AccessAcromegalic Uteropathy: Specific Uterine Ultrasound Findings in Female Patients
Background/Objectives: Acromegaly is a systemic connective-tissue disease driven by chronic growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess, yet the female reproductive tract—especially the extracellular matrix (ECM)-rich cervix—has been poorly studied. We aimed to compare uterine and cervical morphology in women with acromegaly versus healthy controls and a gynecologic disease comparator, testing the hypothesis of selective cervical hypertrophy. Methods: We performed a retrospective case–control study of reproductive-age women who underwent pelvic ultrasound: acromegaly (n=33), healthy controls (n=45), and adenomyosis without acromegaly (n=44). Uterine body and cervical length, width, and anteroposterior (AP) dimensions were measured transvaginally/transabdominally. Volumes were estimated using the ellipsoid formula, and a uterus-to-cervix (U:C) volume ratio was calculated. Group differences were analyzed with Mann–Whitney tests and Bonferroni correction. Results: A total of 122 women were included. Uterine body length, width, AP size, and volume did not differ between acromegaly and either comparison group (all p>0.1). In contrast, cervical length, width, AP thickness, and volume were significantly higher in acromegaly than in healthy controls, with a corresponding reduction in the U:C volume ratio, indicating disproportionate cervical enlargement. Compared with adenomyosis, women with acromegaly again showed larger cervical dimensions and altered U:C indices, suggesting a pattern not explained by nonspecific pelvic pathology. Conclusions: Women with acromegaly demonstrate a distinct uterine phenotype characterized by selective cervical hypertrophy with preserved uterine corpus size—an ECM-centric “acromegalic uteropathy.” This non-invasive morphometric signature may have diagnostic and procedural relevance and warrants confirmation in prospective studies.
- Open Access
- 8 January 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (2) , 199
Artificial Neural Network as a Tool to Predict Severe Toxicity of Anticancer Drug Therapy in Patients with Gastric Cancer: A Retrospective Study
Background. The aim of this study was to develop a predictive model of anticancer drug therapy toxicity in patients with gastric cancer. Methods. The retrospective study included 100 patients with stage II–IV gastric cancer who underwent 4 chemotherapy cycles. Initial significant toxicity factors included age, gender, height, body mass, body mass index, disease stage, skeletal muscle index (SMI), as well as plasma levels of trace elements (copper, zinc, selenium, manganese) and thyroid-stimulating hormone, cancer histology type and treatment regimen. The CTCAE v5.0 scale was employed to assess the severity of adverse events. Statistical analysis and building of mathematical neural network models were carried out in SPSS Statistics (v19.0). Results. Lower SMI values were associated with higher rates of toxicity-related complications of anticancer drug therapy (p < 0.05): leukopenia, hypoproteinemia, nausea, vomiting, cardiovascular events. Anemia, thrombocytopenia, hepatic cytolysis syndrome, nausea, diarrhea, constipation and stomatitis showed a weaker correlation with SMI. An increase in TSH was associated with higher rates of thrombocytopenia, nausea and vomiting. A decrease in Cu/Zn in plasma correlated with the severity of leukopenia and diarrhea, whereas Se/Mn showed an inverse correlation with the severity of anemia. Conclusions. Sarcopenia, abnormal thyroid status and imbalances in copper, zinc, selenium and manganese in blood plasma of patients with gastric cancer may be used as predictors of increased toxicity of anticancer drug therapy.
- 8 January 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (2) , 199
Open AccessArtificial Neural Network as a Tool to Predict Severe Toxicity of Anticancer Drug Therapy in Patients with Gastric Cancer: A Retrospective Study
Background. The aim of this study was to develop a predictive model of anticancer drug therapy toxicity in patients with gastric cancer. Methods. The retrospective study included 100 patients with stage II–IV gastric cancer who underwent 4 chemotherapy cycles. Initial significant toxicity factors included age, gender, height, body mass, body mass index, disease stage, skeletal muscle index (SMI), as well as plasma levels of trace elements (copper, zinc, selenium, manganese) and thyroid-stimulating hormone, cancer histology type and treatment regimen. The CTCAE v5.0 scale was employed to assess the severity of adverse events. Statistical analysis and building of mathematical neural network models were carried out in SPSS Statistics (v19.0). Results. Lower SMI values were associated with higher rates of toxicity-related complications of anticancer drug therapy (p < 0.05): leukopenia, hypoproteinemia, nausea, vomiting, cardiovascular events. Anemia, thrombocytopenia, hepatic cytolysis syndrome, nausea, diarrhea, constipation and stomatitis showed a weaker correlation with SMI. An increase in TSH was associated with higher rates of thrombocytopenia, nausea and vomiting. A decrease in Cu/Zn in plasma correlated with the severity of leukopenia and diarrhea, whereas Se/Mn showed an inverse correlation with the severity of anemia. Conclusions. Sarcopenia, abnormal thyroid status and imbalances in copper, zinc, selenium and manganese in blood plasma of patients with gastric cancer may be used as predictors of increased toxicity of anticancer drug therapy.
- Open Access
- 20 November 2025
- Published by MDPI AG in Preprints.org
Artificial Neural Network as a Tool to Predict Severe Toxicity of Anticancer Drug Therapy in Patients with Gastric Cancer: A Retrospective Study
Background. The aim of the study was to develop a predictive model of anticancer drug therapy toxicity in patients with gastric cancer. Methods. The retrospective study included 100 patients with stage II-IV gastric cancer who underwent 4 chemotherapy cycles. Initial significant toxicity factors included age, gender, height, body mass, body mass index, disease stage, skeletal muscle index (SMI), as well as plasma levels of trace elements (copper, zinc, selenium, manganese) and thyroid-stimulating hormone, cancer histology type and treatment regimen. The CTCAE v5.0 scale was employed to assess the severity of adverse events. Statistical analysis and building of mathematical neural network models were carried out in SPSS Statistics (v19.0). Results. Lower SMI values were associated with higher rates of toxicity-related complications of anticancer drug therapy (р< 0.05): leukopenia, hypoproteinemia, nausea, vomiting, cardiovascular events. Anemia, thrombocytopenia, hepatic cytolysis syndrome, nausea, diarrhea, constipation and stomatitis showed a weaker correlation with SMI. An increase in TSH was associated with higher rates of thrombocytopenia, nausea and vomiting. A decrease in Cu/Zn in plasma correlated with the severity of leukopenia and diarrhea, whereas Se/Mn showed an inverse correlation with the severity of anemia. Conclusion. Sarcopenia, abnormal thyroid status and imbalances in copper, zinc, selenium and manganese in blood plasma of patients with gastric cancer may be used as predictors of increased toxicity of anticancer drug therapy.
- 20 November 2025
- Published by MDPI AG in Preprints.org
Open AccessArtificial Neural Network as a Tool to Predict Severe Toxicity of Anticancer Drug Therapy in Patients with Gastric Cancer: A Retrospective Study
Background. The aim of the study was to develop a predictive model of anticancer drug therapy toxicity in patients with gastric cancer. Methods. The retrospective study included 100 patients with stage II-IV gastric cancer who underwent 4 chemotherapy cycles. Initial significant toxicity factors included age, gender, height, body mass, body mass index, disease stage, skeletal muscle index (SMI), as well as plasma levels of trace elements (copper, zinc, selenium, manganese) and thyroid-stimulating hormone, cancer histology type and treatment regimen. The CTCAE v5.0 scale was employed to assess the severity of adverse events. Statistical analysis and building of mathematical neural network models were carried out in SPSS Statistics (v19.0). Results. Lower SMI values were associated with higher rates of toxicity-related complications of anticancer drug therapy (р< 0.05): leukopenia, hypoproteinemia, nausea, vomiting, cardiovascular events. Anemia, thrombocytopenia, hepatic cytolysis syndrome, nausea, diarrhea, constipation and stomatitis showed a weaker correlation with SMI. An increase in TSH was associated with higher rates of thrombocytopenia, nausea and vomiting. A decrease in Cu/Zn in plasma correlated with the severity of leukopenia and diarrhea, whereas Se/Mn showed an inverse correlation with the severity of anemia. Conclusion. Sarcopenia, abnormal thyroid status and imbalances in copper, zinc, selenium and manganese in blood plasma of patients with gastric cancer may be used as predictors of increased toxicity of anticancer drug therapy.
- 19 August 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (4)
Evaluation of the skeletal muscle index in predicting toxic complications of antitumor drug therapy in patients with gastric cancer
Objective. To assess the relationship between skeletal muscle index (SMI) and the frequency, nature, and severity of toxic complications in patients with locally advanced and metastatic gastric cancer during antitumor drug therapy, a study is being conducted Material and methods. The study included 100 patients diagnosed with gastric cancer who had undergone four courses of chemotherapy. Computed tomography was used for sarcopenia diagnosis. SMI was calculated as the ratio of the average skeletal muscle area at the L3 level to the square of the patient’s height. The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 scale was used to assess the severity of adverse events. Results. Correlation analysis showed a moderate, inverse, statistically significant relationship (p<0.05) between SMI before treatment and the severity of anemia and vomiting after the fourth course of chemotherapy (r=–0.302; r=–0.331). A moderate, inverse relationship (p<0.05) was observed between SMI and the severity of anemia, vomiting (r=–0.323; r=–0.397), and hypoproteinemia (r=–0.300) after four courses of chemotherapy. SMI before treatment correlated weakly (p0.05) with SMI before treatment and after four courses of chemotherapy. Conclusion. The presence of sarcopenia in patients with gastric cancer may serve as a predictor of an increase in the severity of toxicity of antitumor drug therapy. The routinely used bode mass index and body surface area during treatment are not reliable markers for predicting toxicity.
- 19 August 2025
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 14 (4)
Evaluation of the skeletal muscle index in predicting toxic complications of antitumor drug therapy in patients with gastric cancer
Objective. To assess the relationship between skeletal muscle index (SMI) and the frequency, nature, and severity of toxic complications in patients with locally advanced and metastatic gastric cancer during antitumor drug therapy, a study is being conducted Material and methods. The study included 100 patients diagnosed with gastric cancer who had undergone four courses of chemotherapy. Computed tomography was used for sarcopenia diagnosis. SMI was calculated as the ratio of the average skeletal muscle area at the L3 level to the square of the patient’s height. The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 scale was used to assess the severity of adverse events. Results. Correlation analysis showed a moderate, inverse, statistically significant relationship (p<0.05) between SMI before treatment and the severity of anemia and vomiting after the fourth course of chemotherapy (r=–0.302; r=–0.331). A moderate, inverse relationship (p<0.05) was observed between SMI and the severity of anemia, vomiting (r=–0.323; r=–0.397), and hypoproteinemia (r=–0.300) after four courses of chemotherapy. SMI before treatment correlated weakly (p0.05) with SMI before treatment and after four courses of chemotherapy. Conclusion. The presence of sarcopenia in patients with gastric cancer may serve as a predictor of an increase in the severity of toxicity of antitumor drug therapy. The routinely used bode mass index and body surface area during treatment are not reliable markers for predicting toxicity.
- Open Access
- 18 December 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (4) , 478-483
The molecular basis of thyroid status formation and its role in the initiation and promotion of gastric and colorectal cancer: A review
The concept of thyroid status is much broader than assessing the levels of thyroid stimulating hormone, free and bound thyroid hormones in the systemic circulation. It includes features of transport, tissue bioavailability, receptor interaction, metabolism, biomolecular mechanisms of action and inactivation, as well as the physiological or pathophysiological basis of changes in function and the pathomorphological substrate of diseases, including malignancies. Therefore, the question of the mechanisms through which thyroid status influences the processes of tumor initiation and promotion in the gastrointestinal tract is extremely relevant. Regarding colorectal cancer, an ambiguous link between thyroid status has been identified – in some studies, an increase in free T4 concentration and thyrotoxicosis are associated with a decreased risk of developing colon cancer, while in others, the administration of levothyroxine in hypothyroidism had a protective effect. The risk of gastric cancer is elevated in men living in regions with suboptimal or above-normal iodine consumption and suffering from various thyroid pathologies. This paper analyzes modern ideas about pathogenetic relationship between gastric and colon cancer and patients' thyroid status. It presents physiological and biochemical basics of thyroid status formation. Deiodinase expression profile in gastric and colon cancer is stated. The problem of iodine-induced disthyroidoses following radiation procedures using iodine-containing contrasts is described in detail.
- 18 December 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (4) , 478-483
Open AccessThe molecular basis of thyroid status formation and its role in the initiation and promotion of gastric and colorectal cancer: A review
The concept of thyroid status is much broader than assessing the levels of thyroid stimulating hormone, free and bound thyroid hormones in the systemic circulation. It includes features of transport, tissue bioavailability, receptor interaction, metabolism, biomolecular mechanisms of action and inactivation, as well as the physiological or pathophysiological basis of changes in function and the pathomorphological substrate of diseases, including malignancies. Therefore, the question of the mechanisms through which thyroid status influences the processes of tumor initiation and promotion in the gastrointestinal tract is extremely relevant. Regarding colorectal cancer, an ambiguous link between thyroid status has been identified – in some studies, an increase in free T4 concentration and thyrotoxicosis are associated with a decreased risk of developing colon cancer, while in others, the administration of levothyroxine in hypothyroidism had a protective effect. The risk of gastric cancer is elevated in men living in regions with suboptimal or above-normal iodine consumption and suffering from various thyroid pathologies. This paper analyzes modern ideas about pathogenetic relationship between gastric and colon cancer and patients' thyroid status. It presents physiological and biochemical basics of thyroid status formation. Deiodinase expression profile in gastric and colon cancer is stated. The problem of iodine-induced disthyroidoses following radiation procedures using iodine-containing contrasts is described in detail.
- Open Access
- 15 November 2024
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (5) , 157-169
Fundamental aspects of selenium and selenoprotein biochemistry: applied value in oncology
The purpose of the study was to carry out a systematic analysis of the data available in the modern literature on the essentiality of selenium in biological systems and the importance of selenoproteins in oncogenesis.Material and Methods. The publications were analyzed using Scopus (415), PubMed (521), Web of Science (139), eLibrary.ru (240) databases. To obtain full-text documents, the electronic resources PubMed Central (PMC), Science Direct, Research Gate, eLibrary.ru were used.Results. The need to use selenium compounds for the prevention and treatment of malignant neoplasms is controversial, and some selenoproteins have demonstrated a permissive role in oncogenesis, thus requiring further in-depth study in neoplasms of various histogenesis.Conclusion. It is necessary to continue comprehensive molecular studies of bioorganic selenium compounds at the morphological, ultrastructural and biochemical levels in tumors of various localizations, depending on the genetic characteristics of the studied population and the geochemical characteristics of the region.
- 15 November 2024
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (5) , 157-169
Open AccessFundamental aspects of selenium and selenoprotein biochemistry: applied value in oncology
The purpose of the study was to carry out a systematic analysis of the data available in the modern literature on the essentiality of selenium in biological systems and the importance of selenoproteins in oncogenesis.Material and Methods. The publications were analyzed using Scopus (415), PubMed (521), Web of Science (139), eLibrary.ru (240) databases. To obtain full-text documents, the electronic resources PubMed Central (PMC), Science Direct, Research Gate, eLibrary.ru were used.Results. The need to use selenium compounds for the prevention and treatment of malignant neoplasms is controversial, and some selenoproteins have demonstrated a permissive role in oncogenesis, thus requiring further in-depth study in neoplasms of various histogenesis.Conclusion. It is necessary to continue comprehensive molecular studies of bioorganic selenium compounds at the morphological, ultrastructural and biochemical levels in tumors of various localizations, depending on the genetic characteristics of the studied population and the geochemical characteristics of the region.
- Open Access
- 3 July 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (2) , 224-229
Cardiovascular toxicity of chemotherapy and thyroid status of patients with gastric and colon cancer: Current state of the problem. A review
Cardiovascular and oncological diseases are the main causes of disability and mortality in Russia, sharing common risk factors and exacerbating each other. The specific toxicological effects of fluoropyrimidines, platinum drugs, and taxanes commonly used in the treatment of gastric and colorectal malignancies have been noted to potentially contribute to the onset of cardiovascular pathologies in some cases. However, the manifestation and prevalence of cardiovascular toxicity due to cancer treatment regimens are influenced by various factors beyond just the chemotherapy protocols employed. Gender, age, overall health status (including cardiac and thyroid functions), and other risk factors play significant roles in the development and progression of heart and vascular diseases in these patients. Thyroid dysfunction, even in the absence of severe clinical symptoms, can significantly impact the course of cardiovascular pathologies, complicating the management of toxic effects associated with polychemotherapy on both the cardiac muscle and vascular system. This paper analyzes modern ideas about pathogenetic relationship between cardiovascular diseases and gastric and colon cancer. The profile and mechanism of cardiovascular toxicity of chemotherapy in patients with gastric and colon cancer, pathogenetic relationship of thyroid status and cardiovascular diseases are presented. Organizational management issues of chemotherapy toxicity are briefly highlighted.
- 3 July 2024
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 26 (2) , 224-229
Open AccessCardiovascular toxicity of chemotherapy and thyroid status of patients with gastric and colon cancer: Current state of the problem. A review
Cardiovascular and oncological diseases are the main causes of disability and mortality in Russia, sharing common risk factors and exacerbating each other. The specific toxicological effects of fluoropyrimidines, platinum drugs, and taxanes commonly used in the treatment of gastric and colorectal malignancies have been noted to potentially contribute to the onset of cardiovascular pathologies in some cases. However, the manifestation and prevalence of cardiovascular toxicity due to cancer treatment regimens are influenced by various factors beyond just the chemotherapy protocols employed. Gender, age, overall health status (including cardiac and thyroid functions), and other risk factors play significant roles in the development and progression of heart and vascular diseases in these patients. Thyroid dysfunction, even in the absence of severe clinical symptoms, can significantly impact the course of cardiovascular pathologies, complicating the management of toxic effects associated with polychemotherapy on both the cardiac muscle and vascular system. This paper analyzes modern ideas about pathogenetic relationship between cardiovascular diseases and gastric and colon cancer. The profile and mechanism of cardiovascular toxicity of chemotherapy in patients with gastric and colon cancer, pathogenetic relationship of thyroid status and cardiovascular diseases are presented. Organizational management issues of chemotherapy toxicity are briefly highlighted.
- Open Access
- 16 November 2023
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 22 (5) , 161-172
Takotsubo cardiomyopathy in locally advanced rectosigmoid junction cancer: a case report
Background. takotsubo cardiomyopathy (tcm) occurs more frequently in cancer patients than in the general population. The triggers for tcm in cancer patients include not only the inflammatory state of the cancer itself, but also the significant emotional stress of a cancer diagnosis and the physical stress associated with invasive diagnostic and treatment procedures.Case presentation. We describe the case of a 54-yearold woman with histologically verified rectosigmoid junction cancer (cT4bcN2M0) complicated by acute intestinal obstruction. In the early postoperative period, a sudden drop in blood pressure, t-wave inversion and Qt-interval prolongation on ecg, decrease in the left ventricle contractility and presence of wall motion abnormalities on echocardiography (ecHo), as well as an increase in biomarkers of myocardial damage were initially regarded as acute coronary syndrome, which was subsequently excluded according to the findings of coronary angiography, which did not reveal coronary artery obstruction. taking into account the rapid and complete inverse dynamics of changes, acute myocardial infarction without coronary artery obstruction and acute myocarditis were excluded. Ultimately, the diagnosis of takotsubo cardiomyopathy was established.Conclusion. this case report indicates that cancer can be a trigger for the development of tcm; therefore, the assessment of cardiological status and timely detection of cardiac complications in cancer patients during cancer treatment is extremely important and is aimed at increasing the overall survival in this category of patients.
- 16 November 2023
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 22 (5) , 161-172
Open AccessTakotsubo cardiomyopathy in locally advanced rectosigmoid junction cancer: a case report
Background. takotsubo cardiomyopathy (tcm) occurs more frequently in cancer patients than in the general population. The triggers for tcm in cancer patients include not only the inflammatory state of the cancer itself, but also the significant emotional stress of a cancer diagnosis and the physical stress associated with invasive diagnostic and treatment procedures.Case presentation. We describe the case of a 54-yearold woman with histologically verified rectosigmoid junction cancer (cT4bcN2M0) complicated by acute intestinal obstruction. In the early postoperative period, a sudden drop in blood pressure, t-wave inversion and Qt-interval prolongation on ecg, decrease in the left ventricle contractility and presence of wall motion abnormalities on echocardiography (ecHo), as well as an increase in biomarkers of myocardial damage were initially regarded as acute coronary syndrome, which was subsequently excluded according to the findings of coronary angiography, which did not reveal coronary artery obstruction. taking into account the rapid and complete inverse dynamics of changes, acute myocardial infarction without coronary artery obstruction and acute myocarditis were excluded. Ultimately, the diagnosis of takotsubo cardiomyopathy was established.Conclusion. this case report indicates that cancer can be a trigger for the development of tcm; therefore, the assessment of cardiological status and timely detection of cardiac complications in cancer patients during cancer treatment is extremely important and is aimed at increasing the overall survival in this category of patients.